{"protocolSection": {"identificationModule": {"nctId": "NCT01822548", "orgStudyIdInfo": {"id": "2012-005399-32"}, "organization": {"fullName": "Azienda Ospedaliero-Universitaria di Parma", "class": "OTHER"}, "briefTitle": "Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes", "officialTitle": "Randomized, Open Label, Two Parallel Arms, Intervention Trial Comparing the Effect of DPP-IV Inhibitor Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number in Patients With Type 2 Diabetes in Metformin Failure"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-03-28", "studyFirstSubmitQcDate": "2013-03-28", "studyFirstPostDateStruct": {"date": "2013-04-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-03-06", "resultsFirstSubmitQcDate": "2017-04-19", "resultsFirstPostDateStruct": {"date": "2017-08-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-19", "lastUpdatePostDateStruct": {"date": "2017-08-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ivana Zavaroni", "investigatorTitle": "Prof.", "investigatorAffiliation": "Azienda Ospedaliero-Universitaria di Parma"}, "leadSponsor": {"name": "Azienda Ospedaliero-Universitaria di Parma", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the effect of Dipeptidyl peptidase (DPP) -IV inhibitor Vildagliptin vs. Glibenclamide on circulating endothelial progenitor cells (EPCs) number in type 2 diabetes patients in metformin failure. Subjects will be followed for 12 months after randomization.", "detailedDescription": "Diabetic patients show a higher cardiovascular risk compared with non-diabetic patients. It is therefore crucial that blood glucose lowering drugs reveal a favorable cardiovascular risk profile independently of metabolic control.\n\nEPCs are a subset of circulating mononuclear cells derived from the bone marrow. EPCs play a fundamental role in the formation of new blood vessels (neo-endothelization) and repairing of existing blood vessels (re-endothelization) in order to maintain endothelial homeostasis and integrity. Endothelial damage and tissue ischemia, through the release of growth factors and cytokines, represent a strong stimulus for the mobilization of EPCs from the bone marrow. Reduced EPC number has been related to the presence of traditional risk factors for cardiovascular disease and to the development of atherosclerosis and has been shown to predict cardiovascular (CV)risk. Type 2 diabetes is known to be associated with an increased CV risk and a reduced EPC number. Recent data suggest that DPP-IV inhibitors might be involved in the mechanisms promoting bone-marrow EPC mobilization. This putative ancillary effect of DPP-IV might have a favorable impact on type 2 diabetes, a condition characterized by an increased CV risk.\n\nThis is a randomized, open-label, active-treatment-controlled, two parallel arm (2:1), intervention trial comparing DPP-IV inhibitor Vildagliptin (100 mg daily) with Glibenclamide (maximum daily dose of 10 mg). Treatment allocation and titration regimens are not blinded.\n\nPrimary end-point:Absolute change in the EPC number at visit: V0 (randomization), V2 (month 4), V3 (month 8) and V4 (month 12).\n\nSecondary end-point: Absolute change in HbA1C compared to baseline."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"], "keywords": ["EPC", "diabetes", "DPP IV inhibitors"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 64, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vildagliptin & metformin", "type": "EXPERIMENTAL", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration", "interventionNames": ["Drug: Vildagliptin", "Drug: Metformin"]}, {"label": "Glibenclamide & metformin", "type": "ACTIVE_COMPARATOR", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration", "interventionNames": ["Drug: Glibenclamide", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Vildagliptin", "description": "100 mg daily", "armGroupLabels": ["Vildagliptin & metformin"], "otherNames": ["LAF237A"]}, {"type": "DRUG", "name": "Glibenclamide", "description": "2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.", "armGroupLabels": ["Glibenclamide & metformin"]}, {"type": "DRUG", "name": "Metformin", "description": "concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)", "armGroupLabels": ["Glibenclamide & metformin", "Vildagliptin & metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change in the Endothelial Progenitor Cell (EPC) Number", "description": "The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.", "timeFrame": "V0, V2 (month 4), V4 (12 month)"}], "secondaryOutcomes": [{"measure": "Absolute Change in HbA1C Compared to Baseline", "description": "The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months", "timeFrame": "V0 (randomization), V2 (month4), V4 (month 12)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age equal or above 35 years;\n* Diagnosis of type 2 diabetes mellitus as defined by the American Diabetes Association , with at least one year of disease duration at the time of the screening visit;\n* Blood glucose lowering treatment with Metformin alone (monotherapy) at a stable dose of at least 1.5 g/day (or maximum tolerated dose) in the 3 months prior to the screening visit;\n* Insufficient metabolic control as defined by recent (last six months) HbA1c \u2265 7% in any peripheral laboratory and confirmed at the time of the screening;\n* Absence of a recent clinically-relevant progression of micro- and macro-vascular complications (see exclusion criteria);\n* Written informed consent to participate to the study.\n\nExclusion criteria:\n\n* Age below 35 years\n* Type 1 diabetes or other causes of diabetes (pancreatectomy, gestational diabetes, etc.)\n* HbA1c \\< 7% or \u2265 9% at the screening visit\n* Treatment with any blood glucose lowering treatment other than Metformin in the six months before screening visit\n* BMI \\< 20 or \u2265 40 kg/m2, or current/ past history of clinically-relevant eating disorders (including -but no limited to- nervous anorexia, bulimia, binge-eating disorders, etc.)\n* Significant progression of diabetic macro-angiopathy or cardiovascular disease in the six months prior to study visit\n* Significant progression of diabetic micro-angiopathy in the six months prior to study visit\n* Organ failure or other severe diseases limiting life expectancy;\n* Beginning, in the three months before screening visit, of any kind of drug which can modify glycemic levels (beta-blockers, diuretics...), or acute disease (acute infection, urinary tract infection...) in three months before screening visit\n* History of inflammatory/infective/autoimmune chronic disease\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, gastric surgery, inflammatory bowel disease;\n* Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at screening that in the judgment of the investigator would preclude safe completion of the study;\n* Uncontrolled or inadequately controlled hypertension at screening (Systolic Blood Pressure (SBP)\\>190 or Diastolic Blood Pressure (DBP) \\>100 mmHg)\n* Ongoing pregnancy or absence of effective contraception in women with childbearing potential\n* Contraindications to the maintenance of the background therapy (Metformin), including -but not limited to- chronic kidney failure or plasma creatinine concentrations \\> 1.5 mg/dL, severe respiratory failure, etc.;\n* Contraindications to the use of a Sulfonylurea;\n* Contraindications to the use of a DPP-IV Inhibitor;\n* Laboratory findings, or other disease conditions, at the screening visit that might interfere with study measurements:\n\n  1. Hemoglobinopathy known to affect HbA1c assays;\n  2. Known chronic liver diseases, including HBV (hepatitis B virus) and HCV (hepatitis C virus) infection;\n  3. Liver makers (aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), Gamma-glutamyltransferase (GGT) , bilirubin) above 2 times the upper normal limit;\n  4. Amylase and/or lipase above 2 times the upper normal limit;\n* Chronic use of systemic and/or inhaled corticosteroids (only topical corticosteroids are allowed);\n* History of low compliance, clinically-relevant psychiatric disorders or any current/ historical finding suggesting the patient as inappropriate to follow the study procedures.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "35 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Ivana Zavaroni, MD", "affiliation": "Azienda Ospedaliera-Universitaria di Parma", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Azienda Opedaliera-Universitaria", "city": "Parma", "zip": "43126", "country": "Italy", "geoPoint": {"lat": 44.79935, "lon": 10.32618}}, {"facility": "Azienda Ospedaliera-Universitaria", "city": "Parma", "zip": "43126", "country": "Italy", "geoPoint": {"lat": 44.79935, "lon": 10.32618}}]}, "referencesModule": {"references": [{"pmid": "28231835", "type": "DERIVED", "citation": "Dei Cas A, Spigoni V, Cito M, Aldigeri R, Ridolfi V, Marchesi E, Marina M, Derlindati E, Aloe R, Bonadonna RC, Zavaroni I. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol. 2017 Feb 23;16(1):27. doi: 10.1186/s12933-017-0503-0."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Individuals with type 2 diabetes were recruited in the outpatient Diabetes Unit of Parma University Hospital", "groups": [{"id": "FG000", "title": "Vildagliptin & Metformin", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nVildagliptin: 100 mg daily"}, {"id": "FG001", "title": "Glibenclamide & Metformin", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nGlibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Received allocated intervention n=38 Did not receive allocated intervention (only metformin) n=2", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "Discontinued Intervention", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Vildagliptin & Metformin", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nVildagliptin: 100 mg daily"}, {"id": "BG001", "title": "Glibenclamide & Metformin", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nGlibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "64"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61", "spread": "9"}, {"groupId": "BG001", "value": "63", "spread": "10"}, {"groupId": "BG002", "value": "62", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "43"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "64"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "64"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Italy", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.1", "lowerLimit": "26.8", "upperLimit": "32.9"}, {"groupId": "BG001", "value": "28.9", "lowerLimit": "25.4", "upperLimit": "34.1"}, {"groupId": "BG002", "value": "29.0", "lowerLimit": "26.2", "upperLimit": "33.9"}]}]}]}, {"title": "HBA1C", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.7", "lowerLimit": "7.4", "upperLimit": "7.9"}, {"groupId": "BG001", "value": "7.7", "lowerLimit": "7.5", "upperLimit": "8.1"}, {"groupId": "BG002", "value": "7.7", "lowerLimit": "7.4", "upperLimit": "8.1"}]}]}]}, {"title": "Endothelial Progenitor Cells Number", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "EPC/10^6 cells", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39", "lowerLimit": "24.0", "upperLimit": "58.2"}, {"groupId": "BG001", "value": "37.5", "lowerLimit": "25.0", "upperLimit": "59.8"}, {"groupId": "BG002", "value": "38", "lowerLimit": "24.2", "upperLimit": "58.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change in the Endothelial Progenitor Cell (EPC) Number", "description": "The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.", "populationDescription": "Intention to treat (ITT) analysis", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "EPC/10^6 cells", "timeFrame": "V0, V2 (month 4), V4 (12 month)", "groups": [{"id": "OG000", "title": "Vildagliptin & Metformin", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nVildagliptin: 100 mg daily"}, {"id": "OG001", "title": "Glibenclamide & Metformin", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nGlibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "V2 (4 month)", "categories": [{"measurements": [{"groupId": "OG000", "value": "37", "lowerLimit": "27.0", "upperLimit": "65.0"}, {"groupId": "OG001", "value": "36", "lowerLimit": "23.0", "upperLimit": "54.2"}]}]}, {"title": "V4 (12 month)", "categories": [{"measurements": [{"groupId": "OG000", "value": "45", "lowerLimit": "29.7", "upperLimit": "67"}, {"groupId": "OG001", "value": "32", "lowerLimit": "22.2", "upperLimit": "53.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.05", "statisticalMethod": "Regression, Linear", "statisticalComment": "Generalized linear model (GLM)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "ANOVA", "statisticalComment": "adjustment for baseline value of EPC", "paramType": "Slope", "paramValue": "0.362", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.028", "ciUpperLimit": "0.695"}]}, {"type": "SECONDARY", "title": "Absolute Change in HbA1C Compared to Baseline", "description": "The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage", "timeFrame": "V0 (randomization), V2 (month4), V4 (month 12).", "groups": [{"id": "OG000", "title": "Vildagliptin & Metformin", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nVildagliptin: 100 mg daily"}, {"id": "OG001", "title": "Glibenclamide & Metformin", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nGlibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"title": "V2 (4 month)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "lowerLimit": "6.4", "upperLimit": "7.3"}, {"groupId": "OG001", "value": "6.8", "lowerLimit": "6.4", "upperLimit": "7.3"}]}]}, {"title": "V4 (12 month)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "lowerLimit": "6.5", "upperLimit": "7.3"}, {"groupId": "OG001", "value": "7.1", "lowerLimit": "6.5", "upperLimit": "7.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.05", "statisticalMethod": "ANOVA", "paramType": "Slope", "paramValue": "-0.067", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.358", "ciUpperLimit": "0.224"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "4 months", "description": "Hypoglycemia", "eventGroups": [{"id": "EG000", "title": "Vildagliptin & Metformin", "description": "Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nVildagliptin: 100 mg daily", "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 0, "otherNumAtRisk": 40}, {"id": "EG001", "title": "Glibenclamide & Metformin", "description": "Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration\n\nGlibenclamide: 2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 5, "otherNumAtRisk": 24}], "otherEvents": [{"term": "hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "At each study visit side effects were systematically investigated and patients were asked to contact the centre in case of adverse events.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 24}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Prof.ssa Ivana Zavaroni", "organization": "Azienda ospedaliero-universitaria di Parma", "email": "ivana.zavaroni@unipr.it", "phone": "+390521033306"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077597", "term": "Vildagliptin"}, {"id": "D000005905", "term": "Glyburide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "100%", "relevance": "HIGH"}, {"id": "M9017", "name": "Glyburide", "asFound": "E-health", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}